On the path toward meaningful treatments.

Our goal is to discover, develop and deliver innovative therapies that redefine the treatment of cancer. Currently, we are conducting clinical trials of our investigational drug candidates in PD-1 refractory metastatic melanoma and other solid tumors. We are grateful to the participating patients, investigators and clinic staff who are helping us to advance this important research. For more information about any of our clinical studies or study site locations, go to the U.S. FDA Clinical Trials Registry, contact us directly at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

 

For more information about any of our clinical studies or study site locations, go to the U.S. FDA Clinical Trials Registry ,contact us directly at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

Current open trials

Anti-PD-1 Refractory Metastatic Melanoma

 

 

A Phase 1/2 clinical trial of intratumoral tilsotolimod (IMO-2125) in combination with ipilimumab (a CTLA-4 antibody) or pembrolizumab (PD-1 blocking antibody) in patients with metastatic melanoma is underway and enrolling patients at eight clinical locations within the United States. The trial is expected to enroll approximately 60 patients with the goal of determining the maximum tolerated dose, as well as the efficacy of tilsotolimod when administered intratumorally in combination with either ipilimumab or pembrolizumab.  For more information on this study and for a list of currently recruiting trial locations, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

 

 

A Phase 3 clinical trial of intratumoral tilsotolimod in combination with ipilimumab (a CTLA-4 antibody) is patients with anti-PD-1 refractory metastatic melanoma is underway and recruiting patients at over 80 clinical trial sites in the United States, Europe, Australia and Canada.  This trial is expected to enroll approximately 300 patients to determine the overall response rate (ORR) and overall survival rate (OS) of the combination of tilsotolimod and ipilimumab versus ipilimumab alone.  For more information on this trial and for a list of currently recruiting trial locations, go to the U.S. FDA Clinical Trial Registry Website, contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

 

 

Refractory Solid Tumors

A Phase 1b open-label trial designed to evaluate the safety and clinical activity of intratumoral tilsotolimod in patients with refractory solid tumors.  Additionally the study will evaluate multiple tilsotolimod dose levels with the objective of identifying best dose for future clinical trials.  For more information on this study and for a list of currently recruiting trial locations, go to the U.S. FDA Clinical Trial Registry Website, contact Idera at clinicaltrials@iderapharma.com or visit Idera Clinical Trials Website.

 

 

  • Our Team

    Meet the team that’s dedicated to finding the next breakthrough for patients in need.